Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- 10 hours ago
- 1 min read
20/07/2026
US FDA Fast Track Designation Secured for Pelareorep in Advanced Anal Cancer (Ref)
Oncolytics Biotech's Pelareorep (double-stranded RNA immunotherapy), in combination with a checkpoint inhibitor, received Fast Track designation for second-line and later squamous cell carcinoma of the anal canal (SCAC) patients who progressed after prior systemic therapy
The designation is supported by encouraging efficacy demonstrated in the GOBLET study
Objective response rate: ~30% (double historical rates)
Median duration of response: 15.5 months vs 9.5 months historically
12-month overall survival: 82% vs 45.7% historically
This is the third Fast Track designation for pelareorep in GI cancers (pancreatic, KRAS-mutated colorectal, and now anal cancer)
Oncolytics is pursuing registrational studies in GI cancers and seeking strategic partnerships to accelerate development and maximize commercial impact
US FDA Grants Tentative Approval for NATCO’s Generic Olaparib (Ref)
The US FDA granted tentative approval to NATCO Pharma Limited for generic olaparib (Lynparza; PARP inhibitor) tablets in 100‑mg and 150‑mg strengths
Tentative approval confirms the generic meets standards for bioequivalence, safety, efficacy, and quality compared to AstraZeneca’s Lynparza
Olaparib is a well-established & heavily utilized across multiple oncology indications, including specific types of ovarian, breast, pancreatic, and prostate cancers
Comments